Benedikt Westphalen, MD, PhD, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, discusses how comprehensive genomic profiling can improve outcomes for patients with cancer of unknown primary (CUP). In scenarios where origin sites cannot be confirmed, treatment options are limited and standard of care is first line platinum-based chemotherapy. Studies investigating patients with CUP who had undergone comprehensive genomic profiling showed that they had targetable alterations, but could not undergo treatment due to the stage of disease. An example is the CUPISCO trial (NCT03498521). In the future, early access to genomic profiling must be easier to access for patients with CUP, as they may benefit from targeted treatments whilst medically fit. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
